Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine added to ABVD for newly diagnosed intermediate- and high-risk classical Hodgkin lymphoma
ChiCTR-TRC-09000400Phase 4Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of gemcitabine in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Complete remission rate and Overall survival. Started Jan 2009; status: completed.
02
Drugs
gemcitabine
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on ChiCTR-TRC-09000400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000400.